Trevi Therapeutics (TRVI) Tax Provisions (2018 - 2026)
Trevi Therapeutics' quarterly Tax Provisions came in at -$20000.0 in Q1 2026, down 81.82% year-on-year from -$110000.0 in Q1 2025, and down 25.0% quarter-over-quarter from -$16000.0 in Q4 2025.
Trevi Therapeutics has reported Tax Provisions for 9 years, with the latest figure at -$20000.0 in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions fell 81.82% year-over-year to -$20000.0; the trailing twelve-month figure through Mar 2026 stood at -$72000.0 (down 111.76% YoY), and the FY2025 full-year result was -$64000.0, down 113.33% from the prior year.
- Tax Provisions for Q1 2026 stood at -$20000.0, down from -$16000.0 in the prior quarter.
- The five-year high for Tax Provisions was $18000.0 in Q4 2023, with the low at -$31000.0 in Q3 2024.
- Average Tax Provisions over 5 years is -$10705.9, with a median of -$11000.0 recorded in 2025.
- Peak annual rise in Tax Provisions reached 190.0% in 2023, while the deepest fall reached 650.0% in 2023.
- Tracing TRVI's Tax Provisions over 5 years: stood at -$20000.0 in 2022, then jumped by 190.0% to $18000.0 in 2023, then slipped by 11.11% to $16000.0 in 2024, then slumped by 200.0% to -$16000.0 in 2025, then slipped by 25.0% to -$20000.0 in 2026.
- The last three Tax Provisions figures came in at -$20000.0 (Q1 2026), -$16000.0 (Q4 2025), and -$15000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | -20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Sep 30, 2025 | -15,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Sep 30, 2024 | -31,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2023 | -30,000.00 |
| Mar 31, 2023 | -7,000.00 |
| Dec 31, 2022 | -20,000.00 |
| Sep 30, 2022 | -7,000.00 |
| Jun 30, 2022 | -4,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | -15,000.00 |
| Dec 31, 2020 | 17,000.00 |
| Sep 30, 2020 | -11,000.00 |
| Jun 30, 2020 | -15,000.00 |
| Mar 31, 2020 | -9,000.00 |
| Dec 31, 2019 | -4,000.00 |
| Sep 30, 2019 | -5,000.00 |
| Jun 30, 2019 | -5,000.00 |
| Mar 31, 2019 | -4,000.00 |
| Dec 31, 2018 | -49,000.00 |
| Sep 30, 2018 | -25,000.00 |
| Jun 30, 2018 | -25,000.00 |
| Mar 31, 2018 | -25,000.00 |